Trial Profile
An Open-Label, Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Biologic Agents
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jun 2021
Price :
$35
*
At a glance
- Drugs Betamethasone-dipropionate/calcipotriol (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- 29 Dec 2017 Status changed from not yet recruiting to completed.
- 17 Mar 2017 New trial record